Effect of general and epidural anesthesia on hemostasis and fibrinolysis in hepatic patients.
This study was designed to compare the effect of general anesthesia using isoflurane and epidural anesthesia using ropivacaine on hemostasis in hepatic patients. Sixty patients were randomly allocated into two groups to receive either general or epidural anesthesia which further subdivided into control and hepatic subgroups. Blood samples were collected preoperatively, immediate post-operatively and on third post-operative day to measure hemoglobin (Hb), platelet count (PLT),), prothrombin time (PT), partial thromboplastin time (PTT), and thrombin time (TT). Specific hemostatic and fibrinolytic parameters were also included; von Willebrand factor (vWF), soluble platelet selectin (sP-selectin), prothrombin fragment (PF(1+2)), tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and D-dimer. Hemoglobin showed a significant post-operative decrease in all subgroups. Post-operative changes of PLT, PT, PTT and TT were comparable between general and epidural anesthesia. General anesthesia showed a marked significant increase in specific parameters compared to epidural anesthesia. This study concluded that epidural ropivacaine anesthesia provided better hemostatic stability especially in hepatic patients.
Khafagy
Hanan F
HF
Department of Anesthesiology, Theodor Bilharz Research Institute, Giza, Egypt. hananfkhafagy993@hotmail.com
Hussein
Nadia A
NA
Radwan
Khalda G
KG
Refaat
Ahmed I
AI
Hafez
Hoda S
HS
Essawy
Fayza M
FM
Kamel
Hend H
HH
D000328:Adult; D000577:Amides / Q000008:administration & dosage*; D000767:Anesthesia, Epidural / Q000379:methods; D000768:Anesthesia, General / Q000379:methods; D018685:Anesthetics, Inhalation / Q000008:administration & dosage; D000779:Anesthetics, Local / Q000008:administration & dosage; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects*; D006454:Hemoglobins / Q000032:analysis; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D007530:Isoflurane / Q000008:administration & dosage*; D008107:Liver Diseases / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010976:Platelet Count; D011517:Prothrombin Time; D000077212:Ropivacaine; D013918:Thrombin Time; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000097:blood; D001744:Urinary Bladder Calculi / Q000601:surgery
D000577:Amides; D018685:Anesthetics, Inhalation; D000779:Anesthetics, Local; D005338:Fibrin Fibrinogen Degradation Products; D006454:Hemoglobins; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; C036309:fibrin fragment D; D000077212:Ropivacaine; D007530:Isoflurane; D010959:Tissue Plasminogen Activator